Research programme: hepatitis B therapeutics - REPLICor

Drug Profile

Research programme: hepatitis B therapeutics - REPLICor

Alternative Names: REP 9C analogue

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator REPLICor; University of Adelaide
  • Class Nucleic acids; Polymers
  • Mechanism of Action Hepatitis B virus replication inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-B in Canada (Intraperitoneal)
  • 09 Nov 2015 REPLICor receives patent allowance for methods of combination therapy using immunotherapeutic agents and agents that lower serum HBsAg in USA
  • 17 Apr 2008 Preclinical trials in Hepatitis B in Canada (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top